After the immense success of PARP inhibitors at ESMO 2019, synthetic lethality has become the talk of the town. From industry analysts to healthcare researchers, everyone is now interested in this emerging space. In this article, we will look at the financial backing that this domain has received over the last few years and also identify the key backers.
Over 60% of the total capital amount invested in this domain was in the last four years (2016-H1 2019
Over USD 1.5 billion has been raised by companies through venture capital financing
More than 150 investors have supported diverse initiatives undertaken by small / mid-sized companies
Over time, several non-profit organizations have extended financial support to aid research efforts in this domain